Literature DB >> 10948350

Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.

E Reed1, M Dabholkar, K Thornton, C Thompson, J J Yu, F Bostick-Bruton.   

Abstract

Nucleotide excision repair (NER) is the DNA repair pathway through which cisplatin-DNA intrastrand adduct is repaired. Clinical studies have shown that increased mRNA expression of selected genes involved in the rate-limiting step of NER, appear to be closely associated with clinical resistance to platinum agents. These specific studies have led to the possibility of an assessment of the order in which, the appearance of mRNAs of selected NER genes may occur. Included in this assessment are ERCC1, XPB, CSB, and XPA, studied in 28 ovarian cancer tumor tissue specimens. The study of these four genes, in pairs, from 28 ovarian cancer specimens, results in 168 separate observations. Based on the mRNA expression patterns of these genes in these tissues, it is suggested that ERCC1 mRNA may appear before the mRNA of any of the other genes, in an obligate fashion. This is followed by XPB mRNA; which appears before the mRNA of XPA; which in turn, may appear before CSB. This pattern is consistent with what we have reported previously, in non-malignant human bone marrow specimens from a cohort of 52 patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948350     DOI: 10.3892/or.7.5.1123

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

1.  Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Chunqiao Tian; Franco Muggia; Rajiv Dhir; Deborah K Armstrong; Michael A Bookman; Laura J Niedernhofer; Julie Deloia; Michael Birrer; Thomas Carl Krivak
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

2.  Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer.

Authors:  Satoshi Arakawa; Soji Ozawa; Jin Kawase; Hisanori Oshima; Hidetoshi Nagata; Koji Atsuta; Shunji Umemoto
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

3.  Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer.

Authors:  Jian Wang; Xi-Qiao Zhou; Jing-Ying Li; Jian-Feng Cheng; Xiao-Ning Zeng; Xiao Li; Ping Liu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

4.  Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.

Authors:  Wei Hong; Kai Wang; Yi-ping Zhang; Jun-yan Kou; Dan Hong; Dan Su; Wei-min Mao; Xin-min Yu; Fa-jun Xie; Xiao-jian Wang
Journal:  J Zhejiang Univ Sci B       Date:  2013-03       Impact factor: 3.066

5.  Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype.

Authors:  Yi-Wei Yao; Yi-Fu He; Xing-Hua Han; Chu-Shu Ji; Bing Hu
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

6.  Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.

Authors:  Shrey Modi; Devika Kir; Bhuwan Giri; Kaustav Majumder; Nivedita Arora; Vikas Dudeja; Sulagna Banerjee; Ashok K Saluja
Journal:  J Gastrointest Surg       Date:  2015-10-26       Impact factor: 3.452

7.  Nucleotide excision repair and anti-cancer chemotherapy.

Authors:  E Reed
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

8.  Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.

Authors:  Daniel P Feldmann; Joshua Heyza; Christoph M Zimmermann; Steve M Patrick; Olivia M Merkel
Journal:  Molecules       Date:  2020-04-24       Impact factor: 4.411

9.  Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer.

Authors:  Giannis Mountzios; Meletios-Athanasios Dimopoulos; Christos Papadimitriou
Journal:  Biomark Insights       Date:  2008-04-17

10.  The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.

Authors:  Clorinda Schettino; Maria A Bareschino; Paolo Maione; Antonio Rossi; Fortunato Ciardiello; Cesare Gridelli
Journal:  Curr Genomics       Date:  2008-06       Impact factor: 2.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.